title: Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT.
abstract: A 51-year-old man with a recurrent metastatic esthesioneuroblastoma (olfactory neuroblastoma) was referred for peptide receptor radionuclide therapy (PRRT). He received 4 treatments of 111In-octreotide over 8 months and 3 treatments of 177Lu-DOTATATE over 4 months, which helped alleviate his symptoms and improved his quality of life; however, the tumor ultimately progressed and he passed away shortly thereafter. PRRT with 111In-octreotide or 177Lu-DOTATATE could play a role in the management of esthesioneuroblastoma.
authors: From the Department of Diagnostic Imaging, Cross Cancer Institute, Edmonton, AB, Canada.
authors: William
authors: W
authors: Makis
authors: Karey
authors: K
authors: McCann
authors: Alexander J B
authors: AJ
authors: McEwan
mesh_terms: D018304:Esthesioneuroblastoma, Olfactory / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity / Q000473:pathology*; D009669:Nose Neoplasms / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*
chemical_list: D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C094279:indium-111-octreotide; C447941:lutetium Lu 177 dotatate; D015282:Octreotide